Paragon Bioteck Drug Patent Portfolio

Paragon Bioteck owns 1 orange book drug protected by 1 US patent Given below is the list of Paragon Bioteck's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8859623 Methods and compositions of stable phenylephrine formulations 14 Nov, 2033
Active


Given below is the list of recent legal activities going on the following drug patents of Paragon Bioteck.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 03 Oct, 2022 US8859623
7.5 yr surcharge - late pmt w/in 6 mo, Large Entity 03 Oct, 2022 US8859623
Application Return TO OIPE 18 Jul, 2022 US8859623
Correspondence Address Change 18 Jul, 2022 US8859623
Application Return from OIPE 18 Jul, 2022 US8859623
Maintenance Fee Reminder Mailed 06 Jun, 2022 US8859623
Appeal to Court of Appeals 13 Jan, 2017 US8859623
Termination or Final Written Decision 14 Nov, 2016 US8859623
Application ready for PDX access by participating foreign offices 31 Aug, 2015 US8859623
Petition Requesting Trial 11 May, 2015 US8859623
Recordation of Patent Grant Mailed 14 Oct, 2014 US8859623
Patent Issue Date Used in PTA Calculation 14 Oct, 2014 US8859623
Email Notification 25 Sep, 2014 US8859623
Issue Notification Mailed 24 Sep, 2014 US8859623
Dispatch to FDC 15 Sep, 2014 US8859623


Paragon Bioteck's Drug Patent Litigations

Paragon Bioteck's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on May 11, 2015, against patent number US8859623. The petitioner Altaire Pharmaceuticals, Inc., challenged the validity of this patent, with Paragon BioTeck, Inc. as the respondent. Click below to track the latest information on how companies are challenging Paragon Bioteck's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8859623 May, 2015 Final Written Decision
(14 Nov, 2016)
Paragon BioTeck, Inc. Altaire Pharmaceuticals, Inc.


Paragon Bioteck's Family Patents


Family Patents



Paragon Bioteck Drug List

Given below is the complete list of Paragon Bioteck's drugs and the patents protecting them.


1. Phenylephrine Hydrochloride

Phenylephrine Hydrochloride is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8859623 Methods and compositions of stable phenylephrine formulations 14 Nov, 2033
(9 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Phenylephrine Hydrochloride's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List